Clinical Trials Sponsored by TESARO/GlaxoSmithKline

Total 4962 results

GlaxoSmithKline

Withdrawn

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

Infections, Respiratory Tract
GlaxoSmithKline

Completed

Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007

Infections, Rotavirus
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Withdrawn

A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions

Infections, Bacterial
GlaxoSmithKline

Completed

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

AIDS

Spain, Germany, France, United States
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
GlaxoSmithKline

Withdrawn

A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children

Virus Diseases
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD

Pulmonary Disease, Chronic Obstructive

Argentina, France, Germany, Russian Federation, Ukraine, Italy, Norway
GlaxoSmithKline

Completed

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Ukraine, Spain, South Africa, Italy
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.

Infections, Rotavirus

Dominican Republic
GlaxoSmithKline

Completed

MDD POC Study GSK372475 Subjects Depressive Disease

Depressive Disorder

Bulgaria, Canada, Chile, Costa Rica, Italy, Germany, India, France, Croatia, Poland
GlaxoSmithKline

Completed

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

Asthma

Sweden
GlaxoSmithKline

Completed

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS)

United States, Canada
GlaxoSmithKline

Completed

To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)

Dentin Sensitivity

United States
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Asthma

United States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM)

Asthma

United States, Argentina, Australia, Germany, Poland, Romania, Russian Federation, Ukraine, Canada, Chile, France, Korea, Republic of, United Kingdom
GlaxoSmithKline

Completed

Asthma Exacerbation Study

Asthma

United States, Argentina, Germany, Japan, Poland, Romania, Russian Federation, Mexico, Ukraine, Australia, Philippines
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
GlaxoSmithKline

Completed

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Poland, Romania, Russian Federation, Ukraine, Taiwan, Bulgaria, South Africa, Korea, Republic of
GlaxoSmithKline

Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Russian Federation, Ukraine, United States, South Africa, Korea, Republic of, Romania, Canada, France, Italy, Chile, Denmark
GlaxoSmithKline

Completed

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Immune Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

Rhinitis, Allergic, Perennial

United States
GlaxoSmithKline

Completed

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

Atherosclerosis

Japan
GlaxoSmithKline

Completed

A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.

Nutritional Status

India
GlaxoSmithKline

Completed

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Drug Interactions

Korea, Republic of
GlaxoSmithKline

Completed

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, France, Australia, Canada, Belgium, Germany, Korea, Republic of, Japan, Netherlands, Italy, United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Influenza

United States, Canada
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Gastroparesis

United States
GlaxoSmithKline

Terminated

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Arthritis, Rheumatoid

United States, Denmark, Hungary, United Kingdom, Poland
GlaxoSmithKline

Terminated

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Infections, Intestinal

United States, Czechia, Russian Federation, Spain, Canada, France, Italy
GlaxoSmithKline

Completed

Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer

Neoplasms, Colorectal

France
GlaxoSmithKline

Completed

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Diabetes Mellitus, Type 2

United States, Germany, Canada, Belgium, Denmark, Spain, Ireland, Netherlands, United Kingdom, Hungary, Italy, France, Austria, Czechia, Norway, Finland, Sweden
GlaxoSmithKline

Completed

Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Canada, Japan
GlaxoSmithKline

Completed

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

Macular Degeneration

Italy, United States, Belgium, Australia
GlaxoSmithKline

Completed

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Lung Cancer, Non-Small Cell

Germany, United Kingdom, Italy, Poland
GlaxoSmithKline

Completed

A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo

Dermatitis, Atopic

Germany
GlaxoSmithKline

Completed

Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

Neoplasms, Colorectal

India, United Kingdom
GlaxoSmithKline

Completed

A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Neoplasms, Breast

United States
GlaxoSmithKline

Completed

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

Anaemia

United States
GlaxoSmithKline

Completed

A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder

Depressive Disorder, Major

United States
GlaxoSmithKline

Completed

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

Carcinoma, Renal Cell

United States
GlaxoSmithKline

Completed

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom
GlaxoSmithKline

Completed

A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors

Lung Cancer, Non-Small Cell

Germany, United Kingdom
GlaxoSmithKline

Completed

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Solid Tumours

United States
GlaxoSmithKline

Completed

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Cancer

United States
GlaxoSmithKline

Completed

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

Australia, United States, United Kingdom

3

Subscribe